All News
Romosuzumab and Low Sclerostin Levels Underlie CV Risk
d
EurekAlert!
New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.
Read Article
Lupus During Pregnancy Carries Higher Maternal, Fetal Morbidity Risks
d
MedPage Today
Women with systemic lupus erythematosus (SLE) had higher risks for maternal and fetal morbidity compared to those without the chronic autoimmune disorder, according to a nationwide analysis of U.S. data.
Read Article
Pericarditis Management
On the final day of ACR 2023 State of the Art Conference, Dr. Paul Cremer reviewed pericarditis management. Dr. Cremer, a cardiologist at the Cleveland Clinic Foundation, reviewed the questions patients ask about pericarditis including why the disease develops, will it recur, how is it treated, and what will their treatment duration be.
Read Article
ACR 2023 Convergence Brings Back the Poster Hall and 4 Day Meeting
ACR Convergence 2023, the annual meeting of the ACR and the world’s premier rheumatology experience, will be held Nov. 10 – 15 at the San Diego Convention Center in San Diego, CA.
https://t.co/2yFL5m5Y4f https://t.co/rzTbvRv3nT
Links:
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - Audience RA Questions from RNL23
Audience Questions & Answers from RNL23 on Rheumatoid Arthritis
https://t.co/vh1Tzstbwl https://t.co/IUXfAlzPoE
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: What to do about pre-clinical RA?
Much like the recent ACR Convergence, RheumNow Live’s 2023 conference led with this year’s hot topic of rheumatoid arthritis and especially what to do regarding pre-clinical RA.
https://t.co/haxRSMWV3G https://t.co/xci4L0HBGW
Links:
Dr. John Cush RheumNow ( View Tweet)
PJP Prophylaxis Needed with Steroids and RTX
The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving RTX.
https://t.co/eq42bK7MB1 https://t.co/Wk1hOpXanv
Links:
Dr. John Cush RheumNow ( View Tweet)
I want to thank all of our amazing contributors for @RheumNow’s Women in Rheumatology: The XX Factor month. @KDAO2011 @gwenesta_melton and I agree that the future looks brighter when we come together as a community.
Dr. Rachel Tate uptoTate ( View Tweet)
RheumThoughts: Giving Good Care in Diversity takes Time
Dr. Yvonne Sherrer and second-year fellow Dr. Corin Agoris discuss a case where extended time led to improved patient outcomes.
https://t.co/j4QvtBCy6n https://t.co/kECx0yLqJg
Links:
Dr. John Cush RheumNow ( View Tweet)
Stop RA trail:
Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 @RheumNow https://t.co/0uQshODl1j https://t.co/sXIYyQeemJ
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
There are a lot of RA Rx on market now - do we need more?
Dr. Brenner: YES
Stromal targets like LIF/LIFR, Notch3, cadherin-11 offer upstream benefits for our difficult to treat RA patients that don't respond to tradition cs/bDMARDs https://t.co/xavJrFX84G https://t.co/gAdMU4AgXz
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Brenner at #RNL2023
Excellent description on how fibroblasts are major producers of IL-6 producers
Clinically presents a target for blocking the fibroblasts, upstream the inflammatory cascade in RA
@RheumNow https://t.co/9eQDkEzLBS https://t.co/nOGsjJH7AI
Links:
Dr. John Cush RheumNow ( View Tweet)
5 year retrospective study of hip replacements (w/ RA, PsA, OA, AS pts), looked at those w perioperative TNFi vs stopped TNFi; showing no differences in outcomes (p = 0.713)> @ last F/U, revision rates were TNFi 2.5%, nonbiologics 3% & 0.8% OA THAs https://t.co/fMKJLyMO6A https://t.co/FofBlxmNEt
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow
Dr. Stanley Cohen: possible adverse effects of JAKi
-Herpes zoster, other infections
-Malignancy
-Occasional cytopenias
-LFTs (with DMARDs)
-Incr Cr or CPK
-Acne
-Incr lipids
-GI perf
-VTE
Which do you counsel with your patients? https://t.co/WNqQ8HVP9n https://t.co/qWYLoMWELv
Links:
Dr. John Cush RheumNow ( View Tweet)
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 @RheumNow https://t.co/72m0GnmBkZ https://t.co/IThonRjpWD
Links:
Dr. John Cush RheumNow ( View Tweet)
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention! Kevin Deane, MD
#RNL2023
Dr. John Cush RheumNow ( View Tweet)
Korean retrospective claims analysis of #RA (n=54 .7K; 39K RF/CCP+) (2010-2019; F/U 4.3 yrs) saw Parkinsons dx in 290 RA; Compared to controls, RA had a significant 1.74-fold higher risk of PD (found in seropos HR 1.95) but not seroneg RA https://t.co/GRahCXDuYt https://t.co/ohWK51frFr
Links:
Dr. John Cush RheumNow ( View Tweet)
Treatment with MTX in early CCP+ RA thought to be effective in slowing disease however StopRA study did not show a difference between HCQ and PBO in patients. We need to know more about HCQ vs MTX in this space! #RNL2023 https://t.co/hkypaEwZ8F
cc: @uptoTate https://t.co/hgZNyU8YwU
Links:
Dr. John Cush RheumNow ( View Tweet)
STOP-RA study on HCQ preventing RA...
HCQ did NOT prevent RA development in pre-RA pts
@RheumNow #RNL2023 https://t.co/h1YicTORuw https://t.co/JRIFJzMudO
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2023: Kevin Deane: Anti-CCP positive leads to a 20-30% risk for articular clinical RA within 3-5 years https://t.co/YrA7tXMKoI
Cc: @ericdeinmd https://t.co/oXoeZYW7rU
Links:
Dr. John Cush RheumNow ( View Tweet)
